Arnd Kaltofen
Co-Founder and Managing Partner @ VI Partners
Switzerland
Arnd Kaltofen is a Series A investor at VI Partners in Switzerland focused on Health Care and Medical Device. Arnd Kaltofen is the Co-Founder and Managing Partner of VI Partners. He previously worked at Inositec AG as a Board Director and Observer. Arnd Kaltofen attended Northwestern University - Kellogg School of Management.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Arnd Kaltofen invests in
Stages Arnd Kaltofen invests in
Countries Arnd Kaltofen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (39%)
- Medical Device 4 (22%)
- Medical 3 (17%)
- Therapeutics 2 (11%)
- Biotechnology 2 (11%)
Stage
- Series A 4 (22%)
- Series C 2 (11%)
- Venture - Series Unknown 2 (11%)
- Seed 1 (6%)
- Series B 1 (6%)
Country
- Germany 4 (22%)
- Switzerland 2 (11%)
- United States 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| XO-Life.com is an online destination center. That provides services includes digital treatment monitoring and patient feedback R&D, marketing and sales. That offers services for Patient Insights, information exchange between patients and pharma, treatments and indications. | $4.7M / Venture - Series Unknown / Apr 14, 2026 | ||
| XO-Life.com is an online destination center. That provides services includes digital treatment monitoring and patient feedback R&D, marketing and sales. That offers services for Patient Insights, information exchange between patients and pharma, treatments and indications. | $7.8M / Venture - Series Unknown / Aug 22, 2024 | ||
| Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with. | $4.5M / Series A / Oct 25, 2022 | ||
| Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. | $14M / Series A / Mar 30, 2022 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M / Venture - Series Unknown / Feb 05, 2020 | ||
| Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. | $6.3M / Series A / May 23, 2019 | ||
| Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. | $750K / Convertible Note / May 22, 2018 | ||
| Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. | $1.2M / Seed / Dec 16, 2016 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $26.5M / Series C / Aug 07, 2015 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $10M / Series C / Apr 08, 2014 | ||
| See all 18 investments → | |||
Co-Investors
About VI Partners
Healthcare & Technology Venture Capital since 2001. We build bridges between entrepreneurs’ dreams and successful companies. We enable savvy investors to partner with the best start-up companies. VI Partners is a Swiss venture capital firm providing university spin-off's as well as other promising start-up companies with capital, coaching and networks. VI Partners is the advisor to multiple funds. The first fund was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ) in 2001.
VI Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Nicod
Co-Founder and Managing Partner
|
|||
|
Arnd Kaltofen
Co-Founder and Managing Partner
|
|||
Cyrill Osterwalder
Principal
|
|||
Diego Braguglia
General Partner
|
|||
|
Olivier Laplace
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Arnd Kaltofen invest in?
Arnd Kaltofen invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series C stage. Most of the 18 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Arnd Kaltofen?
Public channels for Arnd Kaltofen include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Arnd Kaltofen last invest?
The most recent investment recorded for Arnd Kaltofen closed in Apr 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
